K145 hydrochloride 是一种选择性的,具有底物竞争性和口服活性的SphK2抑制剂,IC50为 4.3 μM,Ki为 6.4 μM。K145 hydrochloride 对 SphK1 和其他蛋白激酶没有活性。K145 hydrochloride 可诱导细胞凋亡,并具有强大的抗肿瘤活性。
生物活性 | K145 hydrochloride is a selective, substrate-competitive and orally activeSphK2inhibitor with anIC50of 4.3 μM and aKiof 6.4 μM. K145 hydrochloride is inactive againstSphK1and other protein kinases. K145 hydrochloride induces cellapoptosisand has potently antitumor activity[1]. |
IC50& Target | IC50: 4.3 μM (SphK2)[1] Ki: 6.4 μM (SphK2)[1] |
体外研究 (In Vitro) | K145 (0-10 μM; 24-72 hours; U937 cells) treatment significantly inhibits the growth of U937 cells in a concentration-dependent manner[1]. K145 (10 μM; 24 hours; U937 cells) treatment significantly induces apoptosis in U937 cells[1]. K145 (4-8 μM; 3 hours; U937 cells) treatment decreases the phosphorylation of ERK and Akt[1]. Treatment with K145 (10 μM) causes a decrease of total cellular S1P without significant effects on ceramide levels[1].
Cell Viability Assay[1] Cell Line: | U937 cells | Concentration: | 0 μM, 4 μM, 6 μM, 8 μM, 10 μM | Incubation Time: | 24 hours, 48 hours, 72 hours | Result: | Significantly inhibited the growth of U937 cells in a concentration-dependent manner. |
Apoptosis Analysis[1] Cell Line: | U937 cells | Concentration: | 10 μM | Incubation Time: | 24 hours | Result: | Significantly induced apoptosis in U937 cells. |
Western Blot Analysis[1] Cell Line: | U937 cells | Concentration: | 4 μM, 8 μM | Incubation Time: | 3 hours | Result: | Phosphorylated ERK and Akt were decreased. |
|
体内研究 (In Vivo) | K145 (50 mg/kg; oral gavage; daily; for 15 days; BALB/c-nu mice) treatment significantly inhibits the growth of U937 tumors in nude mice[1].
Animal Model: | BALB/c-nu mice injected with U937 cells[1] | Dosage: | 50 mg/kg | Administration: | Oral gavage; daily; for 15 days | Result: | Inhibited the growth of U937 tumors at 50 mg/kg dose and no apparent toxicity was observed. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 126.7 mg/mL(329.16 mM;Need ultrasonic and warming) DMSO : 50 mg/mL(129.90 mM;Need ultrasonic) 配制储备液 1 mM | 2.5979 mL | 12.9897 mL | 25.9794 mL | 5 mM | 0.5196 mL | 2.5979 mL | 5.1959 mL | 10 mM | 0.2598 mL | 1.2990 mL | 2.5979 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 0.83 mg/mL (2.16 mM); Clear solution
此方案可获得 ≥ 0.83 mg/mL (2.16 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 0.83 mg/mL (2.16 mM); Clear solution
此方案可获得 ≥ 0.83 mg/mL (2.16 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 0.83 mg/mL (2.16 mM); Clear solution
此方案可获得 ≥ 0.83 mg/mL (2.16 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|